Ebola virus: unravelling pathogenesis to combat a deadly disease.

Ebola virus (EBOV) causes severe haemorrhagic fever leading to up to 90% lethality. Increasingly frequent outbreaks and the placement of EBOV in the category A list of potential biothreat agents have boosted interest in this virus. Furthermore, development of new technologies (e.g. reverse genetics systems) and extensive studies on Ebola haemorrhagic fever (EHF) in animal models have substantially expanded the knowledge on the pathogenic mechanisms that underlie this disease. Two major factors in EBOV pathogenesis are the impairment of the immune response and vascular dysfunction. Here, we attempt to summarize the current knowledge on EBOV pathogenesis focusing on these two factors and on recent progress in the development of vaccines and potential therapeutics.

[1]  V. Volchkov,et al.  Molecular characterization of guinea pig-adapted variants of Ebola virus. , 2000, Virology.

[2]  H. Feldmann,et al.  Filovirus-induced endothelial leakage triggered by infected monocytes/macrophages , 1996, Journal of virology.

[3]  Evseev Aa,et al.  [Preparation of hyperimmune horse serum against Ebola virus]. , 1995, Voprosy virusologii.

[4]  P. Formenty,et al.  Human infection due to Ebola virus, subtype Côte d'Ivoire: clinical and biologic presentation. , 1999, The Journal of infectious diseases.

[5]  Daniel Bausch,et al.  Analysis of Human Peripheral Blood Samples from Fatal and Nonfatal Cases of Ebola (Sudan) Hemorrhagic Fever: Cellular Responses, Virus Load, and Nitric Oxide Levels , 2004, Journal of Virology.

[6]  Shinji Watanabe,et al.  Ebola Virus Glycoprotein: Proteolytic Processing, Acylation, Cell Tropism, and Detection of Neutralizing Antibodies , 2001, Journal of Virology.

[7]  R. Koup,et al.  Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates , 2003, Nature.

[8]  A. Sanchez,et al.  Development of a preventive vaccine for Ebola virus infection in primates , 2000, Nature.

[9]  R. Colebunders,et al.  Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee. , 1999, The Journal of infectious diseases.

[10]  M. Tosi Innate immune responses to infection. , 2005, The Journal of allergy and clinical immunology.

[11]  P. Jahrling,et al.  Apoptosis Induced In Vitro and In Vivo During Infection by Ebola and Marburg Viruses , 2000, Laboratory Investigation.

[12]  W. Marasco,et al.  Evidence against Ebola virus sGP binding to human neutrophils by a specific receptor. , 2002, Virology.

[13]  M. Bray Pathogenesis of viral hemorrhagic fever. , 2005, Current opinion in immunology.

[14]  P. Jahrling,et al.  Depletion of peripheral blood T lymphocytes and NK cells during the course of ebola hemorrhagic Fever in cynomolgus macaques. , 2004, Viral immunology.

[15]  G. Kobinger,et al.  Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. , 2006, Virology.

[16]  T. Ksiazek,et al.  Ebola hemorrhagic fever, Kikwit, Democratic Republic of the Congo, 1995: risk factors for patients without a reported exposure. , 1999, The Journal of infectious diseases.

[17]  P. Debré,et al.  Human asymptomatic Ebola infection and strong inflammatory response , 2000, The Lancet.

[18]  M. Goldsmith,et al.  Differential induction of cellular detachment by envelope glycoproteins of Marburg and Ebola (Zaire) viruses. , 2000, The Journal of general virology.

[19]  T. Ksiazek,et al.  Experimental inoculation of plants and animals with Ebola virus. , 1996, Emerging infectious diseases.

[20]  P. Sureau,et al.  Firsthand clinical observations of hemorrhagic manifestations in Ebola hemorrhagic fever in Zaire. , 1989, Reviews of infectious diseases.

[21]  V. Blinov,et al.  The envelope glycoprotein of Ebola virus contains an immunosuppressive‐like domain similar to oncogenic retroviruses , 1992, FEBS letters.

[22]  M. Levi Current understanding of disseminated intravascular coagulation , 2004, British journal of haematology.

[23]  Sina Bavari,et al.  Filovirus-like particles as vaccines and discovery tools , 2005, Expert review of vaccines.

[24]  A. Sanchez,et al.  Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus. , 2000, Vaccine.

[25]  B. Pulendran,et al.  Cutting Edge: Impairment of Dendritic Cells and Adaptive Immunity by Ebola and Lassa Viruses1 , 2003, The Journal of Immunology.

[26]  M. Bray The role of the Type I interferon response in the resistance of mice to filovirus infection. , 2001, The Journal of general virology.

[27]  A. Sanchez,et al.  Ebola virus inhibits induction of genes by double-stranded RNA in endothelial cells. , 1998, Virology.

[28]  B. Murphy,et al.  A Single Intranasal Inoculation with a Paramyxovirus-Vectored Vaccine Protects Guinea Pigs against a Lethal-Dose Ebola Virus Challenge , 2006, Journal of Virology.

[29]  Heinz Feldmann,et al.  Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses , 2005, Nature Medicine.

[30]  P. Jahrling,et al.  Proinflammatory response during Ebola virus infection of primate models: possible involvement of the tumor necrosis factor receptor superfamily. , 2002, Immunology letters.

[31]  E. Ryabchikova,et al.  An analysis of features of pathogenesis in two animal models of Ebola virus infection. , 1999, The Journal of infectious diseases.

[32]  Heinz Feldmann,et al.  Ebola virus: from discovery to vaccine , 2003, Nature Reviews Immunology.

[33]  P. Jahrling,et al.  Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. , 2003, The American journal of pathology.

[34]  Shinji Watanabe,et al.  Reverse Genetics Demonstrates that Proteolytic Processing of the Ebola Virus Glycoprotein Is Not Essential for Replication in Cell Culture , 2002, Journal of Virology.

[35]  P. Rollin,et al.  Markedly elevated levels of interferon (IFN)-γ, IFN-α, interleukin (IL)-2, IL-10, and tumor necrosis factor-α associated with fatal Ebola virus infection , 1999 .

[36]  G. Ruthel,et al.  Ebola and Marburg virus-like particles activate human myeloid dendritic cells. , 2004, Virology.

[37]  H. Feldmann,et al.  Effects of Ebola Virus Glycoproteins on Endothelial Cell Activation and Barrier Function , 2005, Journal of Virology.

[38]  D. Landry,et al.  The pathogenesis of vasodilatory shock. , 2001, The New England journal of medicine.

[39]  A. Steinkasserer,et al.  DC-SIGN and DC-SIGNR Interact with the Glycoprotein of Marburg Virus and the S Protein of Severe Acute Respiratory Syndrome Coronavirus , 2004, Journal of Virology.

[40]  M. Georges-Courbot,et al.  Inflammatory responses in Ebola virus‐infected patients , 2002, Clinical and experimental immunology.

[41]  H. Feldmann,et al.  Ebola and Marburg viruses: pathogenesis and development of countermeasures. , 2005, Current molecular medicine.

[42]  M. Bray,et al.  Pathogenesis of experimental Ebola Zaire virus infection in BALB/c mice. , 2001, Journal of comparative pathology.

[43]  P. Jahrling,et al.  Mechanisms underlying coagulation abnormalities in ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event. , 2003, The Journal of infectious diseases.

[44]  J. Gonzalez,et al.  Fruit bats as reservoirs of Ebola virus , 2005, Nature.

[45]  Steven J M Jones,et al.  Therapy and prophylaxis of Ebola virus infections. , 2005, Current opinion in investigational drugs.

[46]  A. Sanchez,et al.  Biochemical Analysis of the Secreted and Virion Glycoproteins of Ebola Virus , 1998, Journal of Virology.

[47]  H. Feldmann,et al.  Biosynthesis and role of filoviral glycoproteins. , 2001, The Journal of general virology.

[48]  Ignatyev Gm Immune response to filovirus infections. , 1999 .

[49]  P. Jahrling,et al.  Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys , 2003, The Lancet.

[50]  A. Sanchez,et al.  Ebola Virus Selectively Inhibits Responses to Interferons, but Not to Interleukin-1β, in Endothelial Cells , 1999, Journal of Virology.

[51]  J. Maniloff,et al.  Virus taxonomy : eighth report of the International Committee on Taxonomy of Viruses , 2005 .

[52]  G. Ruthel,et al.  Ebola and Marburg viruses replicate in monocyte-derived dendritic cells without inducing the production of cytokines and full maturation. , 2003, The Journal of infectious diseases.

[53]  H. Feldmann,et al.  Marburg and Ebola hemorrhagic fevers: does the primary course of infection depend on the accessibility of organ-specific macrophages? , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[54]  V. Volchkov,et al.  The Ebola virus VP35 protein functions as a type I IFN antagonist. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[55]  H. Schultheiss,et al.  Procoagulant Soluble Tissue Factor Is Released From Endothelial Cells in Response to Inflammatory Cytokines , 2005, Circulation research.

[56]  E. Nabel,et al.  Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury , 2000, Nature Medicine.

[57]  G. Simmons,et al.  Ebola Virus Glycoproteins Induce Global Surface Protein Down-Modulation and Loss of Cell Adherence , 2002, Journal of Virology.

[58]  H. Klenk,et al.  The asialoglycoprotein receptor is a potential liver-specific receptor for Marburg virus. , 1995, The Journal of general virology.

[59]  P. Jahrling,et al.  Pathogenesis of experimental Ebola virus infection in guinea pigs. , 1999, The Journal of infectious diseases.

[60]  Ali S Khan,et al.  A novel immunohistochemical assay for the detection of Ebola virus in skin: implications for diagnosis, spread, and surveillance of Ebola hemorrhagic fever. Commission de Lutte contre les Epidémies à Kikwit. , 1999, The Journal of infectious diseases.

[61]  P. Jahrling,et al.  Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses. , 1996, Archives of virology. Supplementum.

[62]  Peter B Jahrling,et al.  Exotic emerging viral diseases: progress and challenges , 2004, Nature Medicine.

[63]  V. Volchkov,et al.  Recovery of Infectious Ebola Virus from Complementary DNA: RNA Editing of the GP Gene and Viral Cytotoxicity , 2001, Science.

[64]  D. Heymann,et al.  Ebola between outbreaks: intensified Ebola hemorrhagic fever surveillance in the Democratic Republic of the Congo, 1981-1985. , 1999, The Journal of infectious diseases.

[65]  G. Neumann,et al.  The role of reverse genetics systems in studying viral hemorrhagic fevers , 2005, Thrombosis and Haemostasis.

[66]  Y. Kawaoka,et al.  Human Macrophage C-Type Lectin Specific for Galactose and N-Acetylgalactosamine Promotes Filovirus Entry , 2004, Journal of Virology.

[67]  D. Burton,et al.  Ebola Virus, Neutrophils, and Antibody Specificity , 1998 .

[68]  C. Hughes,et al.  Of Mice and Not Men: Differences between Mouse and Human Immunology , 2004, The Journal of Immunology.

[69]  D. Simpson,et al.  Pathophysiology of shock and hemorrhage in a fulminating viral infection (Ebola). , 1985, The Journal of infectious diseases.

[70]  H. Feldmann,et al.  Properties of Replication-Competent Vesicular Stomatitis Virus Vectors Expressing Glycoproteins of Filoviruses and Arenaviruses , 2004, Journal of Virology.

[71]  H. Feldmann,et al.  Infection and Activation of Monocytes by Marburg and Ebola Viruses , 2001, Journal of Virology.

[72]  Philip K. Russell,et al.  Hemorrhagic fever viruses as biological weapons: medical and public health management. , 2002, JAMA.

[73]  A. Rowe,et al.  Clinical virology of Ebola hemorrhagic fever (EHF): virus, virus antigen, and IgG and IgM antibody findings among EHF patients in Kikwit, Democratic Republic of the Congo, 1995. , 1999, The Journal of infectious diseases.

[74]  Stuart T. Nichol,et al.  Rapid Diagnosis of Ebola Hemorrhagic Fever by Reverse Transcription-PCR in an Outbreak Setting and Assessment of Patient Viral Load as a Predictor of Outcome , 2004, Journal of Virology.

[75]  P. Debré,et al.  Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients , 1999, Nature Medicine.

[76]  P. Jahrling,et al.  Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental Ebola virus infections. , 1999, The Journal of infectious diseases.

[77]  P. Jahrling,et al.  Evaluation in Nonhuman Primates of Vaccines against Ebola Virus , 2002, Emerging infectious diseases.

[78]  Howard R. Petty,et al.  Ebola Virus Secretory Glycoprotein (sGP) Diminishes FcγRIIIB-to-CR3 Proximity on Neutrophils1 , 2000, The Journal of Immunology.

[79]  E. Ryabchikova,et al.  Animal pathology of filoviral infections. , 1999, Current topics in microbiology and immunology.

[80]  M. Bray,et al.  Pathogenesis of filoviral haemorrhagic fevers. , 2004, The Lancet. Infectious diseases.

[81]  R. Ahmed,et al.  Monocyte-Derived Human Macrophages and Peripheral Blood Mononuclear Cells Infected with Ebola Virus Secrete MIP-1α and TNF-α and Inhibit Poly-IC-Induced IFN-α in Vitro , 2001 .

[82]  V. Volchkov,et al.  Ectodomain shedding of the glycoprotein GP of Ebola virus , 2004, The EMBO journal.

[83]  A. Sanchez,et al.  Distinct cellular interactions of secreted and transmembrane Ebola virus glycoproteins. , 1998, Science.

[84]  H. Feldmann,et al.  Viral hemorrhagic fever – a vascular disease? , 2003, Thrombosis and Haemostasis.

[85]  P. Rollin,et al.  Ebola hemorrhagic fever in Kikwit, Democratic Republic of the Congo: clinical observations in 103 patients. , 1999, The Journal of infectious diseases.

[86]  V. Volchkov,et al.  Delta-peptide is the carboxy-terminal cleavage fragment of the nonstructural small glycoprotein sGP of Ebola virus. , 1999, Virology.

[87]  M. Bray,et al.  A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. , 1998, The Journal of infectious diseases.

[88]  A. Sanchez,et al.  Persistence and genetic stability of Ebola virus during the outbreak in Kikwit, Democratic Republic of the Congo, 1995. , 1999, The Journal of infectious diseases.

[89]  C. Goldsmith,et al.  Pathologic features of filovirus infections in humans. , 1999, Current topics in microbiology and immunology.